Archives

– Synthetic Long Peptide (SLP®) immunotherapy achieves targeted tumor eradication comparable to checkpoint-blocking immunotherapy

– New findings on antigens relevant for checkpoint blocking pave the way for personalized cancer vaccines

Leiden, The Netherlands, November 27, 2014 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that a recent scientific paper in Nature supports the company´s therapeutic approach to using synthetic long peptides in cancer therapy. It could be shown that personalized SLP® immunotherapy is as capable of inducing efficient tumor eradication as are T cell checkpoint inhibitors such as

Henk Kamp, the Dutch Minister of Economic Affairs, visited ISA Pharmaceuticals on October 14, 2014, talking about stimulation of innovation and support for innovative companies by the Dutch ministry of Economic Affairs.

The visit was broadcast live on Dutch breakfast television “Vandaag de Dag” (Omroep WNL) on NPO 1 (Nederland 1).
A replay is available at http://www.omroepwnl.nl/video/detail/vandaag-de-dag-14-oktober__141014 (Deel 1 starting at minute 14 and Deel 2 starting at minute 11:53).

Leiden, The Netherlands, September 3, 2014 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the appointment of Hendrik-Jan Laseur to its Supervisory Board.

Hendrik-Jan Laseur has an outstanding track record in advising foundations, non-governmental organizations and financial institutions. Among others, he currently serves as a Board member of the Center for Public Integrity (Washington, DC, USA), as a member of the Advisory Board of SustainAbility (London, UK) and as a Board member of the Adessium Foundation (Rotterdam, The Netherlands).

Hendrik-Jan Laseur is the founder of Laseur – Lead the

Leiden, The Netherlands, July 07, 2014 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that the Company has hired Ronald Loggers, the former Chairman of ISA´s Supervisory Board, as Chief Executive Officer.

Previously, Ronald Loggers, M.Sc., MBA, was Managing Director of Multifund B.V., a family-owned investment firm and one of ISA’s major investors. Until June 2013, he served as the Chairman of the Supervisory Board and subsequently assumed the role of Acting CEO of ISA Pharmaceuticals.

From 1998 to 2005, Ronald Loggers worked for private equity firm HAL Investments.

–      Data presented at the AACR Annual Meeting 2014

–      Potential new treatment being developed for patients with late-stage cervical cancer

Leiden, The Netherlands, April 10, 2014 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, has announced new clinical data on its lead product candidate ISA101. ISA101 is a therapeutic cancer vaccine for the treatment of high-risk, HPV16-induced diseases, such as cervical cancer. The data were presented by principal investigator Prof. Sjoerd van der Burg, Ph.D., at this year’s American Association for Cancer Research (AACR) Annual Meeting in San Diego.

The

Leiden, The Netherlands, March 27, 2014 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced that principal investigator Prof. Sjoerd van der Burg, Ph.D., will present new clinical data on ISA101 at this year’s American Association for Cancer Research (AACR) Annual Meeting. ISA101 is a therapeutic cancer vaccine for the treatment of high-risk, HPV16-induced diseases.

The presentation titled “Synergistic effects of properly timed HPV16 SLP vaccination during standard carboplatin-paclitaxel chemotherapy in animals and patients with metastatic cervical carcinoma“ will be given at the Minisymposium MS.IM02.01 “Immune-based Therapies: Responses,

– Granted EU patent provides market exclusivity until 2028 –

Leiden, The Netherlands, February 24, 2014 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced it has been granted a European patent on its lead compound ISA101. The patent ensures market protection of ISA101’s active ingredient in Europe until 2028.

ISA101 is a therapeutic vaccine for the treatment of high-risk, HPV16-induced diseases. The vaccine consists of synthetic long peptides derived from the E6 and E7 oncogenic proteins of the HPV16 virus. This HPV strain is responsible, among others, for